Kymera Therapeutics, Inc. (NASDAQ:KYMR) Director Sells $280,415.00 in Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMRGet Free Report) Director Joanna Horobin sold 8,500 shares of the stock in a transaction on Friday, June 7th. The shares were sold at an average price of $32.99, for a total value of $280,415.00. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Kymera Therapeutics Price Performance

KYMR traded up $0.09 during trading on Friday, hitting $32.96. 310,105 shares of the stock traded hands, compared to its average volume of 667,246. The firm has a market capitalization of $2.02 billion, a P/E ratio of -13.20 and a beta of 2.25. Kymera Therapeutics, Inc. has a 12-month low of $9.60 and a 12-month high of $45.31. The firm has a 50-day moving average of $35.44 and a 200 day moving average of $32.88.

Kymera Therapeutics (NASDAQ:KYMRGet Free Report) last posted its earnings results on Thursday, May 2nd. The company reported ($0.69) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.04. Kymera Therapeutics had a negative net margin of 194.67% and a negative return on equity of 31.92%. The company had revenue of $10.30 million during the quarter, compared to analyst estimates of $14.24 million. During the same period in the prior year, the business posted ($0.70) earnings per share. Kymera Therapeutics’s revenue for the quarter was up 8.4% on a year-over-year basis. As a group, equities analysts predict that Kymera Therapeutics, Inc. will post -2.86 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently issued reports on KYMR shares. Stifel Nicolaus boosted their price target on shares of Kymera Therapeutics from $35.00 to $55.00 and gave the company a “buy” rating in a research report on Friday, February 23rd. JPMorgan Chase & Co. boosted their target price on Kymera Therapeutics from $34.00 to $47.00 and gave the stock an “overweight” rating in a research report on Friday, February 23rd. Truist Financial lifted their price target on shares of Kymera Therapeutics from $41.00 to $54.00 and gave the stock a “buy” rating in a research note on Friday, March 1st. HC Wainwright reaffirmed a “buy” rating and issued a $46.00 price objective on shares of Kymera Therapeutics in a research note on Monday. Finally, Piper Sandler lifted their target price on shares of Kymera Therapeutics from $39.00 to $56.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 27th. Six investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $42.70.

View Our Latest Stock Report on Kymera Therapeutics

Hedge Funds Weigh In On Kymera Therapeutics

Several hedge funds have recently made changes to their positions in KYMR. DekaBank Deutsche Girozentrale lifted its position in shares of Kymera Therapeutics by 7.1% in the 1st quarter. DekaBank Deutsche Girozentrale now owns 23,562 shares of the company’s stock worth $950,000 after purchasing an additional 1,562 shares during the period. Virtu Financial LLC purchased a new stake in Kymera Therapeutics in the first quarter worth about $207,000. Artal Group S.A. boosted its position in Kymera Therapeutics by 19.6% during the 1st quarter. Artal Group S.A. now owns 3,027,135 shares of the company’s stock valued at $121,691,000 after acquiring an additional 496,400 shares in the last quarter. Comerica Bank grew its holdings in shares of Kymera Therapeutics by 13.7% during the 1st quarter. Comerica Bank now owns 3,324 shares of the company’s stock worth $134,000 after acquiring an additional 400 shares during the period. Finally, California State Teachers Retirement System raised its position in shares of Kymera Therapeutics by 5.5% in the 1st quarter. California State Teachers Retirement System now owns 40,423 shares of the company’s stock worth $1,625,000 after acquiring an additional 2,102 shares in the last quarter.

About Kymera Therapeutics

(Get Free Report)

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.

Featured Stories

Insider Buying and Selling by Quarter for Kymera Therapeutics (NASDAQ:KYMR)

Receive News & Ratings for Kymera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kymera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.